Citizens JMP reiterates Market Outperform rating on Artivion stock

Published 28/07/2025, 10:10
Citizens JMP reiterates Market Outperform rating on Artivion stock

Investing.com - Citizens JMP maintained its Market Outperform rating and $33.00 price target on Artivion Inc. (NYSE:AORT) ahead of the company’s second-quarter earnings report scheduled for August 7. The stock currently trades near its 52-week high of $32.94, having delivered a strong 14% return over the past year. According to InvestingPro data, analyst targets range from $30 to $35.

Artivion’s fiscal year 2025 sales guidance projects 11% growth (14% in constant currency), which implies significant acceleration in the second half of the year following first-quarter results that showed only 2% year-over-year growth (4% in constant currency) and second-quarter guidance of 11% year-over-year growth (13% in constant currency). InvestingPro analysis shows the company achieved nearly 6% revenue growth in the last twelve months, with a healthy gross margin of 64%.

The expected second-half revenue improvement will likely be driven by increasing AMDS sales and the processing of tissue backlog in the third quarter, according to Citizens JMP.

The AMDS product, which showed positive early progress in the first quarter, is launching under an HDE designation requiring institutional review board and value analysis committee approvals at the hospital level, potentially extending the implementation timeline.

AMDS is expected to contribute 100-200 basis points to Artivion’s fiscal year 2025 total revenue, with sales likely weighted toward the second half of 2025 due to the approval process requirements.

In other recent news, Artivion Inc. reported first-quarter earnings for 2025 that exceeded Wall Street expectations, posting $99 million in sales against a consensus estimate of $95 million. This growth was driven by the successful launch of the AMDS product and a recovery from previous supply issues. Analysts from JMP Securities and Stifel have maintained positive ratings on Artivion, with price targets set at $33.00 and $30.00, respectively, citing strong performance in the company’s aortic stent graft business. Additionally, Canaccord Genuity initiated coverage with a buy rating and a $35.00 price target, highlighting strategic investments in aortic arch repair.

Artivion also announced a private agreement to exchange approximately $95 million in convertible notes for common stock, with the transaction expected to issue around 4.1 million shares. Shareholders recently approved executive compensation and selected Ernst & Young LLP as the independent accounting firm for the fiscal year 2025. The company continues to focus on expanding its product offerings and addressing past operational challenges. These developments indicate a period of strategic growth and adaptation for Artivion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.